Laddar...
Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes
BACKGROUND: Omarigliptin is a potent, selective, oral dipeptidyl peptidase 4 (DPP4) inhibitor with a half-life that allows weekly dosing. Inflammation or insulin resistance might be pathological mediators of cardiovascular events in patients with type 2 diabetes. METHODS: Whether omarigliptin has an...
Sparad:
| I publikationen: | Diabetol Metab Syndr |
|---|---|
| Huvudupphovsman: | |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
BioMed Central
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7092436/ https://ncbi.nlm.nih.gov/pubmed/32211075 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13098-020-00533-3 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|